India's pharmaceutical industry is currently facing a complex landscape, grappling with global trade disruptions, increasing regulatory hurdles, and escalating operational costs. Despite these headwinds, demand and exports continue to drive growth for many drugmakers.
Angel One Bets on Lincoln Pharmaceuticals
Against this backdrop, brokerage firm Angel One has identified Ahmedabad-based Lincoln Pharmaceuticals as a promising investment. The firm has assigned a 'Buy' rating to Lincoln Pharma, setting a target price of Rs 845, which implies a potential 39% upside from its Rs 610 valuation.
Angel One's optimistic outlook for Lincoln Pharmaceuticals is primarily driven by the company's strategic focus on export expansion and a shift towards higher-value medicines. Lincoln currently exports its products to over 60 countries and aims to broaden its reach to approximately 90 nations. The company has also secured crucial TGA Australia and EU-GMP approvals, paving its way into more regulated and lucrative international markets.
Strong Q1 Performance and Future Projections
Lincoln Pharmaceuticals commenced FY27 with a robust performance. The company reported a consolidated net profit of Rs 36 crore for the first quarter of FY27, marking a significant 30.9% year-on-year increase. Total income for the quarter rose by 19% to Rs 202 crore, while EBITDA saw a 32% jump to Rs 52 crore.
Looking ahead, Angel One anticipates Lincoln to sustain double-digit growth, projecting the company to achieve Rs 1,000 crore in revenue within the next three years. The brokerage also expects EBITDA margins to remain stable at around 19-20% during FY27-FY29.
Acknowledged Risks for the Pharma Sector
While bullish on Lincoln Pharma, Angel One has also flagged potential risks. These include the ongoing pressures of rising raw-material and employee costs, a degree of dependence on other income sources, and the company's historically modest sales and earnings growth. It was also noted that a portion of the recent profit surge stemmed from other income.
For the broader Indian pharmaceutical sector, the emphasis remains on diversifying export markets and strategically moving into higher-value, regulated segments to mitigate global competition and trade-related uncertainties.